← Back to MDEA

MDEA Stats & Data

Mde Eve

PubChem CID 7767

NPS DataHub

MW243.73

FormulaC12H18ClNO2

CAS74341-78-9

IUPAC1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine hydrochloride

SMILES[Cl-].CCNC(C)Cc1ccc2OCOc2c1.[H+]

InChIKeyIBDIPBWIXJRJQM-UHFFFAOYSA-N

Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Amphetamine

Psychoactive Class Psychedelic / Stimulant

Pharmacology

DrugBank

State Solid

Description

3,4-Methylenedioxyamphetamine (also known as MDA, and Tenamfetamine, or colloquially as "Sally", "Sass", or "Sass-a-frass") is a synthetic entactogen of the amphetamine chemical class. It produces long-lived entactogenic, stimulant and mild psychedelic effects that include stimulation, anxiety suppression, enhanced feelings of empathy, affection, and sociability, and euphoria when administered. MDA was first synthesized in 1910 but its psychoactive effects were not discovered until in 1930. It was used in animal and human trials between 1939 and 1941 and from 1949 to 1957. More than 500 human subjects were given MDA in an investigation of its potential use as either an antidepressant or anorectic. By 1958, it was successfully patented as a cough suppressant and ataractic. By 1961 it was patented as an anorectic under the trade name "Amphedoxamine". Contemporary reports suggest that MDA emerged as a recreational drug towards the end of 1967, meaning its use predates its more widely used relative MDMA (Ecstasy). As with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent. However, MDA is significantly more potent by weight and subjective intensity relative to MDMA.

Receptor Profile

Receptor Actions

Inhibitors

Serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI)

Other

Serotonin-dopamine-norepinephrine releasing agent (SNDRA)

Toxicity

PsychonautWiki

Short-term physical health risks of MDEA consumption include dehydration, insomnia, hyperthermia, and hyponatremia. Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive perspiration puts the body at further risk as the stimulatory and euphoric qualities of the drug may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further. The exact toxic dosage is unknown, but considered to be far greater than its active dose.

Organ-specific toxicity

As with MDMA, the neurotoxicity of MDEA use has long been the subject of debate. Scientific study has resulted in the general agreement that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of MDEA is likely to be neurotoxic and cardiotoxic in some form. Like other powerful serotonin releasing agents, MDEA is thought to cause down-regulation of serotonin reuptake transporters in the brain.

Effect Profile

Curated + 9 Reports

Psychedelic 0.8

Moderate body load with low headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Empathogen 6.1

Strong euphoria and sensory enhancement with moderate stimulation, low empathy

Empathy / Social Openness×3

Euphoria / Mood Elevation×2

Stimulation×1

Sensory Enhancement×1

Stimulant 4.8

Strong euphoria and anxiety/jitters with mild stimulation, low focus

Stimulation / Energy×3

Euphoria / Mood Lift×2

Focus / Productivity×2

Anxiety / Jitters×1

Based on reports from:

PiHKAL PiHKAL #106: MDE Erowid Experience Reports PsychonautWiki MDEA

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1d Half tolerance 36d Baseline ~90d

Experience Report Analysis

Erowid

9 Reports

2000–2012 Date Range

2 With Age Data

19 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 9 experience reports (9 Erowid)

9 Reports

19 Effects Detected

8 Positive

8 Adverse

3 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 8

Focus Enhancement 66.7% 70%

Stimulation 66.7% 70%

Color Enhancement 55.6% 70%

Empathy 55.6% 70%

Euphoria 55.6% 70%

Tactile Enhancement 55.6% 70%

Body High 33.3% 70%

Introspection 33.3% 70%

Adverse Effects 8

Confusion 55.6% 70%

Jaw Clenching 55.6% 70%

Increased Heart Rate 44.4% 70%

Anxiety 44.4% 70%

Sweating 44.4% 70%

Nausea 44.4% 70%

Headache 33.3% 70%

Muscle Tension 33.3% 70%

Real-World Dose Distribution

62K Doses

From 12 individual dose entries

Oral (n=7)

Median: 100.0mg 25th: 100.0mg 75th: 137.5mg 90th: 150.0mg

mg/kg median: 1.378 mg/kg 75th: 1.488

Form / Preparation

Most common forms and preparations reported

Read full reports on Erowid →

Legal Status

Controlled internationally under the UN Convention on Psychotropic Substances 1971.

Country	Status	Notes
Austria	MDEA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Brazil	MDEA is illegal to possess, produce or sell as it is listed on Portaria SVS/MS nº 344 as "MDE".
Canada	MDEA is listed on the CSDA in Schedule I.
France	MDEA is scheduled as a "stupéfiant", i.e.	a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
Germany	MDEA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of April 15, 1991.	It is illegal to manufacture, possess, import, export, buy, sell, procure or to dispense it without a license. ( MDE )
Switzerland	MDEA is a controlled substance specifically named under Verzeichnis D.
United Kingdom	MDEA is a Class A drug.
United States	In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA.	MDEA was made a Schedule 1 substance in the United States on October 15, 1987.

References

Data Sources

Cited References

← Back to MDEA